Arcus Biosciences Inc logo

RCUS

Arcus Biosciences Inc

$25.9

Earnings Summary

Revenue
$26.76Mn
Net Profits
$-66.63Mn
Net Profit Margins
-249.01%
PE Ratio
25.43

Highlights

Revenue:

Arcus Biosciences Inc’s revenue jumped 182.83% since last year same period to $26.76Mn in the Q2 2022. On a quarterly growth basis, Arcus Biosciences Inc has generated 48.62% jump in its revenue since last 3-months.

Net Profits:

Arcus Biosciences Inc’s net profit jumped 12.29% since last year same period to $-66.63Mn in the Q2 2022. On a quarterly growth basis, Arcus Biosciences Inc has generated 2% jump in its net profits since last 3-months.

Net Profit Margins:

Arcus Biosciences Inc’s net profit margin jumped 68.99% since last year same period to -249.01% in the Q2 2022. On a quarterly growth basis, Arcus Biosciences Inc has generated 34.06% jump in its net profit margins since last 3-months.

PE Ratio:

Arcus Biosciences Inc’s price-to-earnings ratio after this Q2 2022 earnings stands at 25.43.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Arcus Biosciences Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.94
EPS Estimate Current Year
-0.94

Highlights

EPS Estimate Current Quarter:

Arcus Biosciences Inc’s earning per share (EPS) estimates for the current quarter stand at -0.94 - a -9.3% fall from last quarter’s estimates.

EPS Estimate Current Year:

Arcus Biosciences Inc’s earning per share (EPS) estimates for the current year stand at -0.94.

Key Ratios

Key ratios of the Arcus Biosciences Inc post its Q2 2022 earnings

Earning Per Share (EPS)
-0.93
Return on Assets (ROA)
0.04
Return on Equity (ROE)
0.1
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Arcus Biosciences Inc’s earning per share (EPS) jumped 14.68% since last year same period to -0.93 in the Q2 2022. This indicates that the Arcus Biosciences Inc has generated 14.68% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Arcus Biosciences Inc’s return on assets (ROA) stands at 0.04.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Arcus Biosciences Inc’s return on equity (ROE) stands at 0.1.

Dividend Per Share (DPS):

Arcus Biosciences Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-03
-0.94
-0.93
1.06%
2022-05-09
-0.86
-0.96
-11.63%

Company Information

Arcus Biosciences is an oncology-focused biopharmaceutical company leveraging its deep cross-disciplinary expertise to discover highly differentiated therapies and to develop a broad portfolio of novel combinations addressing significant unmet needs. Arcus currently has four molecules in clinical development: Etrumadenant (AB928), the first dual A2a/A2b adenosine receptor antagonist to enter the clinic, is being evaluated in multiple Phase 2 and 1b studies across different indications, including prostate, colorectal, non-small cell lung, pancreatic and triple-negative breast cancers. AB680, the first small-molecule CD73 inhibitor to enter the clinic, is in Phase 1/1b development for first-line treatment of metastatic pancreatic cancer in combination with zimberelimab and gemcitabine/nab-paclitaxel. Domvanalimab (AB154), an anti-TIGIT monoclonal antibody and new potential immuno-oncology backbone therapy, is in a three-arm randomized Phase 2 study for first-line treatment of PD-L1- 1.

Organisation
Arcus Biosciences Inc
Employees
236
Industry
Health Technology